Sichuan Biokin Pharmaceutical (688506.SH): SI-B036 bispecific antibody injection approved to conduct clinical trials in advanced solid tumors.

17:21 14/05/2026

Baili Tianheng (688506.SH) announced that the company recently received the official approval notice for drug clinical trials issued by the National Medical Products Administration (NMPA). The drug clinical trial for the company's independently developed innovative biopharmaceutical SI-B036 bispecific antibody injection has been approved to be conducted as a monotherapy in advanced solid tumors.

Sichuan Biokin Pharmaceutical (688506.SH) announced that the company recently received the official approval and issuance of the "Clinical Trial Approval Notice" from the National Medical Products Administration (NMPA). The drug clinical trial of the company's independently developed innovative biopharmaceutical SI-B036 bispecific antibody injection has been approved, allowing the drug to be tested as a single agent in late-stage solid tumors. It is reported that SI-B036 bispecific antibody injection is one of the products of the company's globally leading Specific Enhanced Bispecific Antibody (SEBA) platform, which can not only enhance targeting and anti-tumor activity, but also minimize off-target effects.

Semiconductor Manufacturing International Corporation (00981) announced its first quarter financial results. The company reported a net profit attributable to owners of approximately $197 million, up 14.2% quarter-on-quarter and 5% year-on-year.

Evergreen PG (01962) repurchased 2.058 million shares for HKD 0.965 million on May 14th.

CR ASIA (00831): Jiang Xinping appointed as independent non-executive director

Evergreen PG (01962) repurchased 2.058 million shares for HKD 0.965 million on May 14th.

CR ASIA (00831): Jiang Xinping appointed as independent non-executive director